Zumutor Biologics
Active
Cambridge, United States
Zumutor is a leading immuno-oncology company developing molecules that target solid tumors
Zumutor develops antibody molecules targeting different solid-state cancers. The company has developed an in-house Proprietary Discovery Platform (INABLR®) to generate novel antibodies against cancer cells. Zumutor has received USFDA approval for its novel drug ZM008 in August 2023 to initiate a Phase 1, first-in-human, clinical study for the treatment of multiple solid cancers. For more information, please visit https://www.zumutor.com